FDA hands Scholar Rock a CRL for spinal muscular atrophy drug

Another client of Novo Nordisk's manufacturing arm has been hit with a complete response letter due to issues at its site in Indiana. The FDA has rejected Scholar Rock’s lead asset apitegromab after issues were ...